Drug Tolerance in MGluR5 Clinical Trials – Dr Patrick McCamphill 1:1 with FRAXA

May 21, 2021

We suspected that clinical trials of mGluR5 blockers from Novartis and Roche failed because the drug triggered tolerance. Dr. Patrick does find tolerance, and is looking for ways to overcome it.

Read More »
Bear lab (Bear 3rd from left, McCamphill on right)

Scientists Find a New Way to Reverse Symptoms of Fragile X

May 20, 2020

MIT Professor Mark Bear and colleagues have identified a new target for Fragile X therapeutics: GSK3 alpha. Several FRAXA research teams previously identified GSK3 beta as a treatment target.

Read More »
Patrick McCamphill

Pharmacological Tolerance in the Treatment of Fragile X Syndrome

May 9, 2018

FRAXA funded MIT work to probe tolerance to key Fragile X drugs, including mGluR5 inhibitors and arbaclofen, and to identify ways to sustain long-term treatment benefits.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)